» Articles » PMID: 4085525

Theoretical Michaelis-Menten Elimination Model for Propranolol

Overview
Date 1985 Jul 1
PMID 4085525
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A pharmacokinetic model, with Michaelis-Menten elimination, has been developed for drugs and propranolol in particular. The theory is given and the relationship between the area under the theoretical plasma level curve and the absorption rate constant is discussed. This approach allows for an explanation of many of the observed pharmacokinetics of 'Inderal' and particularly 'Inderal' LA; a sustained release preparation of propranolol. In particular, the bioavailability, as measured by area under the curve, is found to be strongly dependent on the absorption half-life in agreement with experimentally observed data.

Citing Articles

Flavone acetic acid: a nonlinear pharmacokinetic model.

Gouyette A, Kerr D, Kaye S, Setanoians A, Cassidy J, Bradley C Cancer Chemother Pharmacol. 1988; 22(2):114-9.

PMID: 3409441 DOI: 10.1007/BF00257307.


Propranolol inhalation challenge in relation to histamine response in children with asthma.

Gerritsen J, Koeter G, Vander Weele L, KNOL K Thorax. 1988; 43(6):451-5.

PMID: 2971275 PMC: 461309. DOI: 10.1136/thx.43.6.451.


Clinical significance of pharmacokinetic models of hepatic elimination.

Morgan D, Smallwood R Clin Pharmacokinet. 1990; 18(1):61-76.

PMID: 2178850 DOI: 10.2165/00003088-199018010-00004.


Nonlinear pharmacokinetics: clinical Implications.

Ludden T Clin Pharmacokinet. 1991; 20(6):429-46.

PMID: 2044328 DOI: 10.2165/00003088-199120060-00001.

References
1.
Mcainsh J, Baber N, Smith R, Young J . Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol. 1978; 6(2):115-21. PMC: 1429409. DOI: 10.1111/j.1365-2125.1978.tb00835.x. View

2.
Gatley M . To be taken as directed. J R Coll Gen Pract. 1968; 16(1):39-44. PMC: 2236545. View

3.
Caldwell J, COBB S, Dowling M, de JONGH D . The dropout problem in antihypertensive treatment. A pilot study of social and emotional factors influencing a patient's ability to follow antihypertensive treatment. J Chronic Dis. 1970; 22(8):579-92. DOI: 10.1016/0021-9681(70)90034-2. View

4.
Suzuki T, Ohkuma T, Isozaki S . Nonlinear first-pass metabolism of propranolol in the rat. J Pharmacobiodyn. 1981; 4(2):131-41. DOI: 10.1248/bpb1978.4.131. View

5.
Evans G, Nies A, SHAND D . The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther. 1973; 186(1):114-22. View